Mohammad Bakri Hammami, MD A retrospective analysis of the Surveillance, Epidemiology, and End Results (SEER) database emphasized the potential impact of specific socio-racial factors, such as race, sex, and age, on survival outcomes in patients with primary myelofibrosis, according to findings presented at the 2023 SOHO Annual Meeting. Data collected from the database between 2000 […]

Biopsy shows myelofibrosis | Image Credit: © tonaquatic – www.stock.adobe.com Retrospective research shows that race, sex, age, and other socio-racial factors can impact survival outcomes in patients with primary myelofibrosis, according to data presented at the 2023 Society of Hematologic Oncology (SOHO) Annual Meeting. Data collected from the Surveillance, Epidemiology, and End Results (SEER) database […]

Olatoyosi Odenike, MD When treating patients who present with accelerated- or blast-phase myeloproliferative neoplasms (MPN AP or MPN BP), Olatoyosi Odenike, MD, professor of medicine and director, Leukemia Program at the University of Chicago Medicine in Illinois, said the 3 most important considerations are the choice of initial therapy, whether the patient is eligible for […]

Anemia is a common issue in patients with myelofibrosis. © relif – stock.adobe.com Anemia is a common and potentially dangerous condition that can occur in patients with myelofibrosis, a type of myeloproliferative neoplasm. While anemia is a blanket term that describes low hemoglobin levels, myelofibrosis-related anemia behaves quite differently than anemia in patients with a […]